The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First‐Line Hypomethylating Agents Fail

BACKGROUND. Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence and cost burden of HMA failure are unknown yet need...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Cogle, Christopher R., Kurtin, Sandra E., Bentley, Tanya G. K., Broder, Michael S., Chang, Eunice, Megaffin, Scott, Fruchtman, Steven, Petrone, Michael E., Mukherjee, Sudipto
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2017
Ämnen:
Academia‐Pharma Intersect
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388372/
https://ncbi.nlm.nih.gov/pubmed/28283585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0211
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk